{"id":53027,"date":"2023-01-18T13:02:37","date_gmt":"2023-01-18T12:02:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/"},"modified":"2023-01-18T13:02:37","modified_gmt":"2023-01-18T12:02:37","slug":"ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/","title":{"rendered":"TA Announces Strategic Growth Investment in Synokem Pharmaceuticals"},"content":{"rendered":"
\n

MUMBAI, India–(BUSINESS WIRE)–TA Associates (\u201cTA\u201d), a leading global growth private equity firm, today announced that it has completed a strategic growth investment in Synokem Pharmaceuticals Ltd. (\u201cSynokem\u201d or \u201cthe Company\u201d). Synokem\u2019s founders will continue as shareholders in the Company alongside TA.\n<\/p>\n

<\/a><\/p>\n

\nFounded in 1983 by Mr. J.M. Arora, Synokem Pharmaceuticals Ltd. is one of India\u2019s leading contract development and manufacturing organizations (CDMOs), serving customers in the branded generic domestic formulations market. In addition, the Company\u2019s products are exported to more than 30 countries. Synokem is based in New Delhi, India, with manufacturing and R&D facilities in Haridwar, India.\n<\/p>\n

\n\u201cWe have been consistently impressed both by Synokem\u2019s commitment to innovation and its excellent and enduring relationship with customers,\u201d said Dhiraj Poddar, Managing Director and Head of Indian operations for TA Associates Advisory Pvt. Ltd. \u201cThat the Company has delivered numerous first-to-market products is further indicative of its industry-leading position. We believe Synokem can serve as a high-quality producer of pharma products, not just for India but also for international markets. We are excited to partner with Synokem\u2019s management team to drive growth, including through strategic acquisitions.\u201d\n<\/p>\n

\n\u201cWith industry expansion being driven by both demographic and economic factors, including higher health insurance penetration and affordability, we believe there is a strong opportunity to build on Synokem\u2019s momentum and further expand its capabilities,\u201d added Vishal Gupta, Director at TA. \u201cWe look forward to complementing the organic growth of the Company with TA\u2019s expertise in strategic acquisitions, as well as our broad network and global resources.\u201d\n<\/p>\n

\n\u201cWe believe TA is an ideal partner for Synokem as we enter the next phase of our journey,\u201d said Abhinav Arora, Managing Director of Synokem. \u201cThe firm\u2019s deep industry knowledge and experience scaling companies like ours will meaningfully boost our ability to pursue both organic and inorganic growth, thereby increasing our market share and further positioning Synokem as an industry leader.\u201d\n<\/p>\n

\nFinancial terms of the transaction were not disclosed. TA is represented by AZB & Partners. BDA Partners acted as the financial adviser to Synokem.\n<\/p>\n

\nAbout TA
\n
<\/b>TA Associates (\u201cTA\u201d) is a leading global growth private equity firm. Focused on targeted sectors within five industries \u2013 technology, healthcare, financial services, consumer, and business services \u2013 the firm invests in profitable, growing companies with opportunities for sustained growth and has invested in more than 560 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $48.6 billion in capital since its founding in 1968. The firm\u2019s more than 110 investment professionals are based in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong.\n<\/p>\n

\nAbout Synokem Pharmaceuticals
\n
<\/b>Synokem Pharmaceuticals is one of India\u2019s largest contract development and manufacturing organizations (CDMOs) serving marquee clients backed by strong R&D capabilities and excellent track record of execution. Synokem was founded in 1983, with a vision of empowering life with quality medicines at competitive prices, and timely availability to each segment of the population. The Company\u2019s operations began with ethical marketing before establishing its CDMO division in 2005.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nTA:<\/b>
Maggie Benoit
\n
Communications Manager
\n
mbenoit@ta.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MUMBAI, India–(BUSINESS WIRE)–TA Associates (\u201cTA\u201d), a leading global growth private equity firm, today announced that it has completed a strategic growth investment in Synokem Pharmaceuticals Ltd. (\u201cSynokem\u201d or \u201cthe Company\u201d). Synokem\u2019s founders will continue as shareholders in the Company alongside TA. Founded in 1983 by Mr. J.M. Arora, Synokem Pharmaceuticals Ltd. is one of India\u2019s … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53027","6":"format-standard","7":"category-industry"},"yoast_head":"\nTA Announces Strategic Growth Investment in Synokem Pharmaceuticals - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TA Announces Strategic Growth Investment in Synokem Pharmaceuticals - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MUMBAI, India–(BUSINESS WIRE)–TA Associates (\u201cTA\u201d), a leading global growth private equity firm, today announced that it has completed a strategic growth investment in Synokem Pharmaceuticals Ltd. (\u201cSynokem\u201d or \u201cthe Company\u201d). Synokem\u2019s founders will continue as shareholders in the Company alongside TA. Founded in 1983 by Mr. J.M. Arora, Synokem Pharmaceuticals Ltd. is one of India\u2019s ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-18T12:02:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230118005205\/en\/1688443\/21\/TA_Associates_Square.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"TA Announces Strategic Growth Investment in Synokem Pharmaceuticals\",\"datePublished\":\"2023-01-18T12:02:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\\\/\"},\"wordCount\":545,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230118005205\\\/en\\\/1688443\\\/21\\\/TA_Associates_Square.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\\\/\",\"name\":\"TA Announces Strategic Growth Investment in Synokem Pharmaceuticals - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230118005205\\\/en\\\/1688443\\\/21\\\/TA_Associates_Square.jpg\",\"datePublished\":\"2023-01-18T12:02:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230118005205\\\/en\\\/1688443\\\/21\\\/TA_Associates_Square.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230118005205\\\/en\\\/1688443\\\/21\\\/TA_Associates_Square.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TA Announces Strategic Growth Investment in Synokem Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TA Announces Strategic Growth Investment in Synokem Pharmaceuticals - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"TA Announces Strategic Growth Investment in Synokem Pharmaceuticals - Pharma Trend","og_description":"MUMBAI, India–(BUSINESS WIRE)–TA Associates (\u201cTA\u201d), a leading global growth private equity firm, today announced that it has completed a strategic growth investment in Synokem Pharmaceuticals Ltd. (\u201cSynokem\u201d or \u201cthe Company\u201d). Synokem\u2019s founders will continue as shareholders in the Company alongside TA. Founded in 1983 by Mr. J.M. Arora, Synokem Pharmaceuticals Ltd. is one of India\u2019s ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-18T12:02:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230118005205\/en\/1688443\/21\/TA_Associates_Square.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"TA Announces Strategic Growth Investment in Synokem Pharmaceuticals","datePublished":"2023-01-18T12:02:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/"},"wordCount":545,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230118005205\/en\/1688443\/21\/TA_Associates_Square.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/","url":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/","name":"TA Announces Strategic Growth Investment in Synokem Pharmaceuticals - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230118005205\/en\/1688443\/21\/TA_Associates_Square.jpg","datePublished":"2023-01-18T12:02:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230118005205\/en\/1688443\/21\/TA_Associates_Square.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230118005205\/en\/1688443\/21\/TA_Associates_Square.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ta-announces-strategic-growth-investment-in-synokem-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"TA Announces Strategic Growth Investment in Synokem Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53027"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53027\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}